Every 424B that Revolution Medicines, Inc. (RVMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RVMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVMD filings page.
Revolution Medicines, Inc. is offering 10,563,381 shares of its common stock pursuant to a prospectus supplement. The public offering price is $142.00 per share, with estimated net proceeds to the issuer of approximately $1,435.0 million after underwriting discounts and estimated offering expenses. The prospectus supplement states an underwriter option to purchase up to 1,584,506 additional shares for 30 days and notes a concurrent, separate offering of $500,000,000 principal amount of 0.50% convertible senior notes due 2033; neither offering is contingent on the other. The company reported 197,001,401 shares outstanding as of December 31, 2025, and the prospectus discloses 28.6 million shares subject to outstanding options, warrants or RSUs as of that date.
Revolution Medicines, Inc. is offering $500,000,000 aggregate principal amount of 0.50% convertible senior notes due May 1, 2033. Interest accrues at 0.50% paid semi‑annually beginning November 1, 2026. The initial conversion rate is 5.0302 shares per $1,000 principal (= ~$198.80 per share). The company may settle conversions in cash, stock or a combination, and may redeem notes under specified stock‑price conditions on or after May 6, 2030. Concurrently, the company has a separate common stock offering of 10,563,381 shares, plus an underwriter option for up to 1,584,506 additional shares. Net proceeds to the company from the notes offering are estimated at approximately $486.8 million, to be used for general corporate purposes.
Revolution Medicines is offering $750,000,000 of common stock, equal to 7,777,662 shares at an assumed public offering price of $96.43 per share. The prospectus supplement also describes a concurrent offering of $250,000,000 aggregate principal amount of convertible senior notes due 2033 (plus a $37,500,000 option).
The company reported 197,001,401 shares outstanding as of December 31, 2025. The shelf registration permits primary sales of common stock; the underwriters have a 30-day option to purchase up to $112,500,000 of additional shares. Completion of the equity offering is not contingent on the concurrent convertible note offering, and vice versa.
Revolution Medicines, Inc. is offering $250,000,000 aggregate principal amount of % convertible senior notes due 2033, with an underwriter option of up to $37,500,000. The notes pay semi‑annual interest, mature May 1, 2033 and are convertible into common stock based on an initial conversion rate and conversion price.
The offering is concurrent with a separate common stock offering of $750,000,000 (plus up to $112,500,000 option). No listing is planned for the notes; common stock trades on Nasdaq under RVMD and last reported sale price was $96.43 per share.
Revolution Medicines, Inc. is registering shares of its common stock for sale under a replacement at-the-market sales agreement with TD Securities (USA) LLC to offer up to $1,000,000,000 in aggregate offering price of common stock, subject to market conditions.
The sales agreement, dated February 25, 2026, replaces a prior agreement dated August 7, 2024. The filing states 197,001,401 shares outstanding as of December 31, 2025 and notes the last reported sale price of $102.74 per share on February 19, 2026. Sales may occur in negotiated transactions, block trades or other methods permitted by law, and TD Cowen may act as agent or principal; compensation is up to 3.0% of gross proceeds.